TrialESMO open2025

COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.

N Peled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.